Clinical trials: Antiviral Agents
Chronic Hepatitis C Virus
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
- Trial name
- NCT01740791
- Testing
- Velpatasvir
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Hepatitis C
Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy
The prevalence of HCV infection in Egypt is 14.7%. HCV is both a hepatotropic and a lymphotropic virus, it may exert a chronic stimulus on the immune system with both T and B lymphocyte alterations.
- Trial name
- NCT03226717
- Testing
- Antiviral agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Thrombocytopenia
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
- Trial name
- NCT01355289
- Testing
- Avatrombopag, Pegylated interferon (PEG-IFN), Telaprevir
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Respiratory Syncytial Virus Infections
A Study of AK0529 in Chinese Infants Hospitalized With RSV
This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China.
- Trial name
- AIRFLO (NCT04231968)
- Testing
- AK0529
- Where
- 28 sites in China
- Volunteers
- 311 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
COVID-19
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Novel antiviral drugs can mark a turning point in the prevention and treatment of patients with Covid-19. Recently, several independent large phase-III RCTs have shown that the intravenous administration of one gift of…
- Trial name
- TURN-COVID (NCT05195060)
- Testing
- casirivimab with imdevimab, sotrovimab, molnupiravir
- Where
- 4 sites in Netherlands
- Volunteers
- 1,178 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hepatitis C
Hepatitis C Rimantadine and Antiviral Combination Therapy
Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible.
- Trial name
- HepRiACT (NCT01413490)
- Testing
- rimantadine
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Heptatitis C
Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease
This randomized controlled trial proposes to compare the treatment outcomes of 12 weeks versus 24 weeks of direct-acting antiviral (DAA) therapy in patients with HCV-related chronic liver disease, addressing the ongoing debate…
- Trial name
- NCT07702396
- Testing
- 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily
- Where
- Pakistan
- Volunteers
- 192 people
- Sponsor
- Indus Hospital and Health Network
Leukemia, Lymphoma
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
RATIONALE: Antiviral agents are drugs that act against viruses and may be an effective treatment for HIV. Peripheral stem cell transplantation or umbilical cord blood transplantation may be able to replace immune cells that were…
- Trial name
- NCT00003435
- Testing
- anti-thymocyte globulin, melphalan, antiviral therapy
- Where
- United States
- Sponsor
- Duke University
Chronic Hepatitis B, Hepatic Steatosis
Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B
The aim of the study was to evaluate the consistency between liver biopsy and Liver Stiffness Measurement (LSM) for fibrosis and controlled attenuation parameter (CAP) for steatosis in FibroScan® in patients with chronic…
- Trial name
- Faraday (NCT06573190)
- Testing
- Transient elastography, Tenofovir Disoproxil Fumarate
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Yaşar Bayındır, MD
Hepatitis B Virus (HBV)
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT00734162
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- 21 sites in United States, Bulgaria and 5 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV Infection
Early Antiviral Therapy for Critically Ill HIV Infected Patients
The aim of the study is to verify the effect of HAART in critically ill HIV infected patients. The current practice is to begin antiviral therapy after ICU discharge, when the condition of the patient is more stable.
- Trial name
- NCT01455688
- Testing
- early HAART, Late HAART
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Hospital Nossa Senhora da Conceicao
Chronic Hepatitis B, Hepatocellular Carcinoma
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia.
- Trial name
- NCT01872988
- Testing
- Tenofovir
- Where
- 4 sites in Taiwan
- Volunteers
- 320 people
- Sponsor
- Taichung Veterans General Hospital
Covid19
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Background: The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019.
- Trial name
- NCT04739410
- Testing
- Ivermectin
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- FMH College of Medicine and Dentistry
Chronic Hepatitis B
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
The purpose of the study was to assess the efficacy and safety of telbivudine at a dose of 20 mg/kg up to a maximum of 600 mg q.d.
- Trial name
- NCT02058108
- Testing
- Telbivudine
- Where
- 29 sites in Bulgaria, Greece and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Syncytial Viruses
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity…
- Trial name
- NCT03333317
- Testing
- Lumicitabine
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.
The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.
- Trial name
- NCT00044135
- Testing
- clevudine (drug)
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 30 people
- Sponsor
- Triangle Pharmaceuticals
Hepatitis C, Drug Use
Future Destinations: Journeys Towards Citizenship
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), if left untreated it can lead to chronic liver disease, cirrhosis and cancer.
- Trial name
- NCT04159545
- Testing
- Qualitative and quantitative interviews
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Dundee
HCV Infection, HCV Coinfection
Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents
Study about the improvement of cognitive, psychopathological and functional abilities in Hepatitis C Virus (HCV) infected patients after eradication of the virus with direct antiviral agents.
- Trial name
- NCT03508115
- Volunteers
- 80 people
- Sponsor
- Corporacion Parc Tauli
End Stage Heart Disease, Hepatitis C
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03208244
- Testing
- Clinically prescribed direct acting antiviral
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.